Advancing mRNA technologies from concept to therapeutic application
The McGill mRNA Therapeutics Platform supports the development and evaluation of a broad range of RNA modalities, providing researchers with the flexibility to explore different approaches for therapeutic applications. Our platform has established and validated workflows for several RNA formats, while continuing to expand into emerging RNA technologies.
mRNA Vaccine
mRNA vaccines use messenger RNA to instruct cells to produce specific antigens, enabling the development of vaccine candidates without introducing the antigen itself. This versatile modality supports applications in infectious diseases, cancer vaccines, and emerging immunotherapeutic strategies.
CAR mRNA
CAR mRNA enables transient expression of chimeric antigen receptors (CARs) in immune cells, providing a flexible approach for investigating CAR-based cell therapies. This modality supports rapid evaluation of different CAR designs and targeted immune-cell engineering strategies.
mRNA based
CRISPR engineering
mRNA enables transient expression of CRISPR genome-editing components within cells, providing a flexible approach for targeted genetic modification. This modality can support gene knockout, targeted gene correction, and precise genome editing for investigating disease mechanisms and developing potential genetic therapies.
Funding
Supported byÂ
Network
In collaboration withÂ
